Wedbush Reiterates an 'Outperform' on Halozyme Therapeutics (HALO); Adding to Best Ideas List; Insulin Opportunity Under the Radar and Undervalued

Wedbush reiterates an 'Outperform' on Halozyme Therapeutics (NASDAQ: HALO) price target raised from $14 to $17.

Wedbush analyst said, "We believe that the insulin pump opportunity is under-appreciated and undervalued. We see little technical, regulatory and commercialization risk to this near-term opportunity potentially worth >$500 million/year in the U.S. alone."

The Wedbush Investment Committee is adding HALO to the Best Ideas List.

For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

Shares of Halozyme Therapeutics closed at $8.80 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Wolverine World Wide (WWW) PT Raised to $31 at UBS on Growth, EPS Upside Potential
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)